Literature DB >> 25458651

Long-term risk of cardiovascular events across a spectrum of adverse major plasma lipid combinations in the Framingham Heart Study.

Charlotte Andersson1, Asya Lyass2, Ramachandran S Vasan3, Joseph M Massaro4, Ralph B D'Agostino2, Sander J Robins1.   

Abstract

BACKGROUND: Blood levels of high low-density lipoprotein cholesterol (LDL-C), high triglycerides (TG), and low high-density lipoprotein cholesterol (HDL-C) have been associated with increased risk of cardiovascular disease (CVD). The long-term comparative CVD risk associated with these 3 major lipid classes in various combinations is, however, unknown.
METHODS: A total of 3,501 participants of the Framingham Offspring Study (mean age 51 ± 10 years, 56% women) without CVD at baseline were followed up for incident CVD between 1987 and 2011. Participants were grouped according to baseline lipid values into 8 distinct categories to compare the prognostic significance of values within an optimal range to Third Report of the National Cholesterol Educational Program-defined high LDL-C (> 130 mg/dL), high TG (> 150 mg/dL), and/or low HDL-C (< 40 mg/dL) in various combinations using multivariable-adjusted Cox regression models.
RESULTS: On follow-up (median 20.2 years), 724 (21%) had new-onset CVD. Adjusted for confounders and compared with the group with optimal lipid values, hazards ratios and population-attributable risks (PARs) were as follows: isolated low HDL-C, 1.93 (95% CI 1.37-2.71), PAR = 3.1%; isolated high LDL-C, 1.28 (1.03-1.59), PAR 6.4%; isolated high TG, 1.35 (0.91-1.98), PAR = 1.1% (not significant); low HDL-C and high LDL-C, 1.82 (1.33-2.49), PAR = 3.9%; low HDL-C and high TG, 1.74 (1.28-2.37), PAR = 3.9%; high LDL-C and high TG, 1.52 (1.12-2.07), PAR = 6.4%; and high LDL-C, high TG and low HDL-C 2.28 (1.73-3.02), PAR = 7.5%.
CONCLUSIONS: Aside from isolated hypertriglyceridemia, low levels of HDL-C, high levels of LDL-C, and high levels of TG in any combination were associated with increased risk of CVD.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25458651     DOI: 10.1016/j.ahj.2014.08.007

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  17 in total

Review 1.  Use of fibrates in the metabolic syndrome: A review.

Authors:  Kate E Shipman; Richard C Strange; Sudarshan Ramachandran
Journal:  World J Diabetes       Date:  2016-03-10

Review 2.  ( -)-Epicatechin and cardiometabolic risk factors: a focus on potential mechanisms of action.

Authors:  Ezequiel J Hid; Juana I Mosele; Paula D Prince; Cesar G Fraga; Monica Galleano
Journal:  Pflugers Arch       Date:  2021-11-23       Impact factor: 3.657

Review 3.  Unique features of high-density lipoproteins in the Japanese: in population and in genetic factors.

Authors:  Shinji Yokoyama
Journal:  Nutrients       Date:  2015-04-02       Impact factor: 5.717

Review 4.  Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease.

Authors:  Peter P Toth
Journal:  Vasc Health Risk Manag       Date:  2016-05-06

5.  Low HDL cholesterol as a cardiovascular risk factor in rural, urban, and rural-urban migrants: PERU MIGRANT cohort study.

Authors:  María Lazo-Porras; Antonio Bernabe-Ortiz; Germán Málaga; Robert H Gilman; Ana Acuña-Villaorduña; Deborah Cardenas-Montero; Liam Smeeth; J Jaime Miranda
Journal:  Atherosclerosis       Date:  2015-12-29       Impact factor: 5.162

6.  Novel and traditional lipid-related biomarkers and their combinations in predicting coronary severity.

Authors:  Sha Li; Yuan-Lin Guo; Xi Zhao; Yan Zhang; Cheng-Gang Zhu; Na-Qiong Wu; Rui-Xia Xu; Ping Qing; Ying Gao; Xiao-Lin Li; Jing Sun; Geng Liu; Qian Dong; Jian-Jun Li
Journal:  Sci Rep       Date:  2017-03-23       Impact factor: 4.379

7.  Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study.

Authors:  Jennifer S Lee; Po-Yin Chang; Ying Zhang; Jorge R Kizer; Lyle G Best; Barbara V Howard
Journal:  Diabetes Care       Date:  2017-01-25       Impact factor: 19.112

8.  A First-in-Class Drug, Lomitapide, Tailored to Patients with Homozygous Familial Hypercholesterolemia is Just about Meeting with Good News to Them.

Authors:  Hiroshi Yoshida
Journal:  J Atheroscler Thromb       Date:  2017-02-24       Impact factor: 4.928

9.  White Blood Cell Counts to High-Density Lipoprotein Cholesterol Ratio, as a Novel Predictor of Long-Term Adverse Outcomes in Patients After Percutaneous Coronary Intervention: A Retrospective Cohort Study.

Authors:  Ting-Ting Wu; Ying-Ying Zheng; Wen-Juan Xiu; Wan-Rong Wang; Yi-Li Xun; Yan-Yan Ma; Patigvl Kadir; Ying Pan; Yi-Tong Ma; Xiang Xie
Journal:  Front Cardiovasc Med       Date:  2021-07-08

10.  Residual cardiovascular risk in individuals on lipid-lowering treatment: quantifying absolute and relative risk in the community.

Authors:  Wolfgang Lieb; Danielle M Enserro; Martin G Larson; Ramachandran S Vasan
Journal:  Open Heart       Date:  2018-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.